Receptors, TNF-Related Apoptosis-Inducing Ligand

"Receptors, TNF-Related Apoptosis-Inducing Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumor necrosis factor receptor family members that are widely expressed and play a role in regulation of peripheral immune responses and APOPTOSIS. The receptors are specific for TNF-RELATED APOPTOSIS-INDUCING LIGAND and signal via conserved DEATH DOMAINS that associate with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.

Descriptor ID	D053220
MeSH Number(s)	D12.776.543.750.690.600 D12.776.543.750.705.852.760.396
Concept/Terms	Receptors, TNF-Related Apoptosis-Inducing Ligand Receptors, TNF-Related Apoptosis-Inducing Ligand Receptors, TNF Related Apoptosis Inducing Ligand Tumor Necrosis Factor Receptor Superfamily, Member 10 TRAIL Receptors Receptors, TRAIL Receptors, Tumor Necrosis Factor, Member 10 TNF-Related Apoptosis-Inducing Ligand Receptors TNF Related Apoptosis Inducing Ligand Receptors Receptors, Tumor Necrosis Factor, Member 10d Receptors, Tumor Necrosis Factor, Member 10d Decoy Receptor 2, Tumor Necrosis Factor Receptor, TRAIL-4 Receptor, TRAIL 4 TRAIL-4 Receptor DCR2 Receptor Receptor, DCR2 CD264 Antigen Antigen, CD264 TRAIL Receptor 4 Receptor 4, TRAIL Receptors, Tumor Necrosis Factor, Member 10a Receptors, Tumor Necrosis Factor, Member 10a Tumor Necrosis Factor Receptor Superfamily, Member 10a APO2 Receptor Receptor, APO2 Receptor, TRAIL-1 Receptor, TRAIL 1 TRAIL-1 Receptor TRAIL Receptor 1 DR4 Receptor Receptor, DR4 CD261 Antigen Antigen, CD261 Death Receptor-4 Death Receptor 4 Receptor-4, Death Receptors, Tumor Necrosis Factor, Member 10b Receptors, Tumor Necrosis Factor, Member 10b TRAIL Receptor 2 Receptor, TRAIL-2 Receptor, TRAIL 2 TRAIL-2 Receptor DR5 Receptor Receptor, DR5 Tumor Necrosis Factor Receptor Superfamily, Member 10b TNF-Related Apoptosis-Inducing Ligand Receptor 2 TNF Related Apoptosis Inducing Ligand Receptor 2 CD262 Antigen Antigen, CD262 Death Receptor-5 Death Receptor 5

Below are MeSH descriptors whose meaning is more general than "Receptors, TNF-Related Apoptosis-Inducing Ligand".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Death Domain [D12.776.543.750.690]
Receptors, TNF-Related Apoptosis-Inducing Ligand [D12.776.543.750.690.600]
Receptors, Immunologic [D12.776.543.750.705]
Receptors, Cytokine [D12.776.543.750.705.852]
Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
Receptors, TNF-Related Apoptosis-Inducing Ligand [D12.776.543.750.705.852.760.396]

Below are MeSH descriptors whose meaning is related to "Receptors, TNF-Related Apoptosis-Inducing Ligand".

Below are MeSH descriptors whose meaning is more specific than "Receptors, TNF-Related Apoptosis-Inducing Ligand".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, TNF-Related Apoptosis-Inducing Ligand" by people in this website by year, and whether "Receptors, TNF-Related Apoptosis-Inducing Ligand" was a major or minor topic of these publications.

Bar chart showing 7 publications over 5 distinct years, with a maximum of 2 publications in 2012 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	1	0	1
2012	2	0	2
2014	1	0	1
2016	2	0	2
2025	0	1	1

Below are the most recent publications written about "Receptors, TNF-Related Apoptosis-Inducing Ligand" by people in Profiles.

Strandberg J, Louie A, Lee S, Hahn M, Srinivasan P, George A, De La Cruz A, Zhang L, Hernandez Borrero L, Huntington KE, De La Cruz P, Seyhan AA, Koffer PP, Wazer DE, DiPetrillo TA, Graff SL, Azzoli CG, Rounds SI, Klein-Szanto AJ, Tavora F, Yakirevich E, Abbas AE, Zhou L, El-Deiry WS. TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury. J Clin Invest. 2025 Jan 14; 135(5).

View in: PubMed
Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, Kumar P, Gabrilovich DI. Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. Clin Cancer Res. 2017 Jun 15; 23(12):2942-2950.

View in: PubMed
Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Mol Cancer Res. 2016 07; 14(7):599-611.

View in: PubMed
Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014 Jun; 124(6):2626-39.

View in: PubMed
Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, Yeo CJ, Gorospe M, Witkiewicz AK, Sachs JN, Brody JR. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Cancer Biol Ther. 2012 Aug; 13(10):946-55.

View in: PubMed
Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc? receptor engagement. Proc Natl Acad Sci U S A. 2012 Jul 03; 109(27):10966-71.

View in: PubMed
Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest. 2008 Jan; 118(1):111-23.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement